Genomictree Inc. - Asset Resilience Ratio

Latest as of December 2025: 50.56%

Genomictree Inc. (228760) has an Asset Resilience Ratio of 50.56% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 228760 working capital efficiency to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

₩61.05 Billion

≈ $41.37 Million USD Cash + Short-term Investments

Total Assets

₩120.76 Billion

≈ $81.84 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2020–2025)

This chart shows how Genomictree Inc.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Genomictree Inc. asset portfolio.

Liquid Assets Composition Over Time

This chart breaks down Genomictree Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read how much debt does Genomictree Inc. carry for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩61.05 Billion	50.56%
Total Liquid Assets	₩61.05 Billion	50.56%

Asset Resilience Insights

Very High Liquidity: Genomictree Inc. maintains exceptional liquid asset reserves at 50.56% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Genomictree Inc. Industry Peers by Asset Resilience Ratio

Compare Genomictree Inc.'s asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	2.50%
Dianthus Therapeutics Inc. NASDAQ:DNTH	Biotechnology	63.98%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	62.24%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%
Wecome Pharmaceutical Co Ltd SHE:300878	Biotechnology	0.67%
Tectonic Therapeutic, Inc. NASDAQ:TECX	Biotechnology	86.66%
Relmada Therapeutics Inc NASDAQ:RLMD	Biotechnology	95.25%
MediWound Ltd F:M8W	Biotechnology	56.04%

Annual Asset Resilience Ratio for Genomictree Inc. (2020–2025)

The table below shows the annual Asset Resilience Ratio data for Genomictree Inc..

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	50.56%	₩61.05 Billion ≈ $41.37 Million	₩120.76 Billion ≈ $81.84 Million	-22.97pp
2024-12-31	73.53%	₩96.08 Billion ≈ $65.11 Million	₩130.68 Billion ≈ $88.56 Million	+3.41pp
2023-12-31	70.12%	₩93.15 Billion ≈ $63.12 Million	₩132.84 Billion ≈ $90.03 Million	-0.23pp
2022-12-31	70.35%	₩114.61 Billion ≈ $77.67 Million	₩162.91 Billion ≈ $110.40 Million	+34.18pp
2021-12-31	36.17%	₩64.08 Billion ≈ $43.43 Million	₩177.15 Billion ≈ $120.05 Million	-3.25pp
2020-12-31	39.42%	₩46.48 Billion ≈ $31.50 Million	₩117.90 Billion ≈ $79.90 Million	--

pp = percentage points

About Genomictree Inc.

KQ:228760 Korea Biotechnology

Market Cap

$194.66 Million

₩287.24 Billion KRW

Market Cap Rank

#16746 Global

#640 in Korea

Share Price

₩11960.00

Change (1 day)

+17.37%

52-Week Range

₩10070.00 - ₩32000.00

All Time High

₩38550.00